Gf Fund Management Co. Ltd. Protagonist Therapeutics, Inc Transaction History
Gf Fund Management Co. Ltd.
- $4.26 Trillion
- Q1 2025
A detailed history of Gf Fund Management Co. Ltd. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 1,526 shares of PTGX stock, worth $81,854. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,526
Previous 1,251
21.98%
Holding current value
$81,854
Previous $48.3 Million
52.82%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PTGX
# of Institutions
298Shares Held
61.3MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$328 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$309 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$307 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$229 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$161 Million5.07% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.63B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...